Haemonetics Corporation
HAE | NYSE
$120.58
+$0.93 (+0.78%)
Nov 2, 2026, 11:22 AM ET · Market open
Fiscal Year Period Ending | FY 2026 Mar 28, 2026 | FY 2025 Mar 29, 2025 | FY 2024 Mar 31, 2024 | FY 2023 Mar 31, 2023 | FY 2022 Mar 31, 2022 | FY 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|
Revenue | 1.33B | 1.36B | 1.31B | 1.17B | 993.2M | 870.46M |
Cost of Revenue | 590.44M | 582.28M | 597.14M | 545.79M | 462.43M | 442.02M |
Gross Profit | 743.59M | 778.55M | 711.92M | 622.87M | 530.77M | 428.45M |
Operating Income | 241.4M | 221.82M | 164.88M | 156.03M | 80.75M | 89.75M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 128.03M | 212.07M | 151.87M | 141.4M | 63.63M | 72.91M |
Net Income | 97.31M | 167.68M | 117.56M | 115.4M | 43.38M | 79.47M |
Selling & General & Admin | 442.42M | 422.05M | 420.82M | 373.95M | 332.2M | 263.83M |
Research & Development | 59.77M | 69.42M | 63.04M | 58.63M | 55.2M | 40.66M |
Other Expenses | n/a | 65.26M | 63.18M | 34.26M | 62.62M | 34.21M |
Operating Expenses | 502.19M | 556.73M | 547.03M | 466.84M | 450.02M | 338.7M |
Interest Expense | 28.7M | 9.75M | 13.02M | 14.63M | 17.12M | 16.83M |
Selling & Marketing Expenses | n/a | 7.7M | 7.1M | 7.2M | 4.4M | 2.7M |
Cost & Expenses | 1.09B | 1.14B | 1.14B | 1.01B | 912.45M | 780.72M |
Income Tax Expense | 30.72M | 44.39M | 34.31M | 26M | 20.25M | -6.56M |
Shares Outstanding (Basic) | 47.18M | 50.33M | 50.71M | 50.78M | 51.05M | 50.69M |
Shares Outstanding (Diluted) | 47.35M | 50.73M | 51.4M | 51.42M | 51.35M | 51.29M |
EPS (Basic) | 2.05 | 3.31 | 2.32 | 2.27 | 0.85 | 1.57 |
EPS (Diluted) | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 | 1.55 |
EBITDA | 312.45M | 355.99M | 295.45M | 252.01M | 191.72M | 184.38M |
EBIT | 156.73M | 247.1M | 206.84M | 167.2M | 105.17M | 100.1M |
Depreciation & Amortization | 155.72M | 108.89M | 88.62M | 84.81M | 86.55M | 84.29M |
Add to Watchlist
Select watchlists to add or remove HAE